These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15459583)

  • 1. Surrogate end points for pulmonary arterial hypertension.
    Kawut SM; Palevsky HI
    Am Heart J; 2004 Oct; 148(4):559-65. PubMed ID: 15459583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate and combined end points in pulmonary arterial hypertension.
    Ventetuolo CE; Benza RL; Peacock AJ; Zamanian RT; Badesch DB; Kawut SM
    Proc Am Thorac Soc; 2008 Jul; 5(5):617-22. PubMed ID: 18625754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical end-points and surrogate markers of pulmonary arterial hypertension in the light of evidence-based treatment].
    Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():36-42. PubMed ID: 20819765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
    Distler O; Behrens F; Pittrow D; Huscher D; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Furst DE;
    Arthritis Rheum; 2008 Jun; 59(6):867-75. PubMed ID: 18512721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.
    Snow JL; Kawut SM
    Clin Chest Med; 2007 Mar; 28(1):75-89, viii. PubMed ID: 17338929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostics in pulmonary hypertension.
    Schannwell CM; Steiner S; Strauer BE
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):591-602. PubMed ID: 18204173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
    Peacock AJ; Naeije R; Galiè N; Rubin L
    Eur Respir J; 2009 Jul; 34(1):231-42. PubMed ID: 19567606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary arterial hypertension: evaluation of the newly diagnosed patient.
    Torbicki A; Kurzyna M
    Semin Respir Crit Care Med; 2005 Aug; 26(4):372-8. PubMed ID: 16121313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
    Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise as an end-point in pulmonary hypertension trials.
    McCullagh B; Girgis RE
    Int J Clin Pract Suppl; 2010 Jan; (165):4-6. PubMed ID: 19958394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension.
    Bernal V; Pascual I; Esquivias P; García-Gil A; Mateo JM; Lacambra I; Serrano MT; Simón MA
    Transplant Proc; 2009 Apr; 41(3):987-8. PubMed ID: 19376405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.
    Mereles D; Ehlken N; Kreuscher S; Ghofrani S; Hoeper MM; Halank M; Meyer FJ; Karger G; Buss J; Juenger J; Holzapfel N; Opitz C; Winkler J; Herth FF; Wilkens H; Katus HA; Olschewski H; Grünig E
    Circulation; 2006 Oct; 114(14):1482-9. PubMed ID: 16982941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of the results of clinical trials: surrogate end points and composite end points.
    Gensini GF; Conti AA
    Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension.
    Souza R; Jardim C; Julio Cesar Fernandes C; Silveira Lapa M; Rabelo R; Humbert M
    Respir Med; 2007 Jan; 101(1):69-75. PubMed ID: 16781131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pulmonary arterial hypertension. Part II: Medical and surgical treatment].
    Manes A; Marinelli A; Palazzini M; Negro L; Leci E; Gambetti S; Bachetti C; Beciani E; Conficoni E; Branzi A; Galiè N
    G Ital Cardiol (Rome); 2009 Jun; 10(6):366-81. PubMed ID: 19603608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine.
    Sulica R; Poon M
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):347-60. PubMed ID: 15853607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right heart function and haemodynamics in pulmonary hypertension.
    Hemnes AR; Champion HC
    Int J Clin Pract Suppl; 2008 Jul; (160):11-9. PubMed ID: 18638171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs.
    Stepien RL
    J Small Anim Pract; 2009 Sep; 50 Suppl 1():34-43. PubMed ID: 19765218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.